Scholarlink

Purpose of Review <p>Neuroendocrine neoplasms (NENs) are heterogeneous tumors requiring accurate staging and disease characterization to guide treatment, including eligibility for peptide receptor radionuclide therapy (PRRT). Imaging—particularly somatostatin receptor (SSTR) PET/CT—plays a key role in multidisciplinary tumor boards (MTBs). This review evaluates the impact of imaging on clinical decision-making in NENs.</p> Recent Findings <p>Seven studies assessing imaging within MTBs were included, with four providing comparable management change data (517 cases). Imaging-attributable management changes ranged from 36% to 59%, with a pooled estimate of 49% (95% CI 35–63%; I² = 78%). Imaging most commonly influenced decisions on PRRT eligibility, surgical planning, liver-directed therapies, and adjustments to systemic treatment.</p> Summary <p>Imaging significantly impacts multidisciplinary decision-making in NENs, altering management in approximately half of cases. Despite heterogeneity across studies, findings support the central role of SSTR PET/CT in guiding treatment. Prospective studies with standardized definitions and patient-centered outcomes are needed to better establish clinical benefit.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Imaging as a Driver of Multidisciplinary Decision-making in Neuroendocrine Neoplasms: A Targeted Evidence Synthesis

  • 期刊论文

  • 发表日期：

    2026年4月21日

查看全文
  • Milin Patel,
  • Kiven Vuong,
  • Bipin Nanda,
  • Ashley Farrell,
  • Kartik Gupta,
  • Ankush Jajodia

摘要

Purpose of Review

Neuroendocrine neoplasms (NENs) are heterogeneous tumors requiring accurate staging and disease characterization to guide treatment, including eligibility for peptide receptor radionuclide therapy (PRRT). Imaging—particularly somatostatin receptor (SSTR) PET/CT—plays a key role in multidisciplinary tumor boards (MTBs). This review evaluates the impact of imaging on clinical decision-making in NENs.

Recent Findings

Seven studies assessing imaging within MTBs were included, with four providing comparable management change data (517 cases). Imaging-attributable management changes ranged from 36% to 59%, with a pooled estimate of 49% (95% CI 35–63%; I² = 78%). Imaging most commonly influenced decisions on PRRT eligibility, surgical planning, liver-directed therapies, and adjustments to systemic treatment.

Summary

Imaging significantly impacts multidisciplinary decision-making in NENs, altering management in approximately half of cases. Despite heterogeneity across studies, findings support the central role of SSTR PET/CT in guiding treatment. Prospective studies with standardized definitions and patient-centered outcomes are needed to better establish clinical benefit.